Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

verubecestat

- PMLiVE

Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer

New data from KEYNOTE-590 trial was presented at ESMO 2020 virtual congress

- PMLiVE

Merck signs separate agreements with Seattle Genetics for two cancer drugs

Merck makes a $1bn equity investment in the biotech company

- PMLiVE

Keytruda improves survival in first-line oesophageal cancer

Topline data demonstrates promising efficacy in the first-line setting

- PMLiVE

Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track

Drug could become first treatment to reduce clinical decline in Alzheimer's

- PMLiVE

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

Biotech company did not disclose the reason for the partnership's end

- PMLiVE

Merck enters agreement with Hanmi for investigational NASH drug

Licensing agreement includes $10m upfront payment

- PMLiVE

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

Milestone payments could reach up to $2bn

Biogen Idec building

Biogen, Eisai take Alzheimer’s candidate BAN2401 into phase 3

Pivotal AHEAD 3-45 programme initiated this week

- PMLiVE

Biogen completes filing for highly-anticipated Alzheimer’s drug

FDA has 60 days to decide whether to accept filing for review

- PMLiVE

Merck, Bayer flesh out vericiguat heart failure data at ACC

Drug reduced rate of cardiovascular deaths and hospitalisations

Alzheimer’s: the search for a cure

Will Biogen’s aducanumab re-energise the hunt for pharma’s white whale?

Great expectations: the urgent need for common purpose in Alzheimer’s disease

By Andrew Harrison

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links